The U.S. Food and Drug Administration (FDA) recently provided an update regarding its plans for conducting routine surveillance inspections of domestic and foreign facilities during the COVID-19 pandemic. FDA announced in March that it would temporarily postpone foreign and domestic inspections, with the exception of certain “mission-critical” inspections, as identified on a case-by-case basis. In its most recent update, FDA Commissioner Stephen Hahn M.D. stated that the agency’s current approach will continue as local, national, and international conditions warrant.